The Mexican approach to conduct allogeneic stem cell transplantation: Braking dogmata and facing the Matthew effect

Hematology

Volumn 10, Issue SUPPL. 1, 2005, Pages 154-160

  Ruiz Argüelles, Guillermo J ^a  

^a CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; IMMUNOGLOBULIN G; METHOTREXATE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGRAFT; APHERESIS; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; PRIORITY JOURNAL; THEORY; TREATMENT OUTCOME;

AMBULATORY CARE; BLOOD COMPONENT TRANSFUSION; DEVELOPING COUNTRIES; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MEXICO; PHARMACEUTICAL PREPARATIONS; TRANSPLANTATION, HOMOLOGOUS;

EID: 29244460381     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330512331390258     Document Type: Article

References (53)

1. Alarcón-Segovia D, Ruiz-Argüelles A, Llorente L. Broken dogma: Penetration of autoantibodies into living cells. Immunol Today 1996;17:163-164.
2. Thomas ED. Hematopoietic stem cell transplantation. Sci Am 1995;272:38-47.
3. Odom LF, August CS, Githens JH, Humbert JR, Morse H, Peakman D, Sharma B, Rusnak SL, Johnson FB. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man? Lancet 1978;2:537-540.
4. Weiden PL, Sullivan KM, Fluornoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft versus host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304:1529-1533.
5. Hematology. Landmark papers of the twentieth century. In: Lichtman MA, Spivak JL, Boxer LA, Shattil SJ, Henderson ES, editors. San Diego, U.S.A.: Academic Press; 2000. pp 741-747.
6. Kolb HJ, Mittermüller J, Clemm CH, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chromic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
7. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995;23:1553-1562.
8. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996;87:2195-2204.
9. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
10. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividelli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998;91:756-763.
11. Quesenberry PJ, Stewart FM, Becker P, Emmons R, Hsieh C, Werme K, Habibian H, Reilly J, McAuliffe C, Dooner M, et al. Stem cell transplantation without myeloablation in immunocompetent recipients. In: En Giralt S, Slavin S, editors. Non myeloablative stem cell transplantation. Abingdon, Oxfordshire, UK: Darwin Scientific Publishing; 2000. pp 11-16.
12. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.
13. Champlin R. Nonmyeloablative chemotherapy with allogeneic hematopoietic transplantation as adoptive immunotherapy for malignancies. In: En Schechter GP, Hoffman R, Schrier SL, editors. Hematology 1999. Washington, U.S.A.: The American Society of Hematology Education Program Book; 1999. pp 413-416.
14. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C, Radich J, Little MT, Nash RA, Cauncey T, et al. Non-myeloablative hematopoietic stem cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann N Y Acad Sci 2001;938:328-337.
15. Storb R, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. In: En Schechter GP, Broudy VC, Williams ME, editors. Hematology 2001. Washington, U.S.A: The American Society of Hematology Education Program Book; 2002. pp 375-391.
16. Childs R, Barrett. Graft-versus-tumor effects following non-myeoablative stem cell transplantation. In: En Giralt S, Slavin S, editors. Non myeloablative stem cell transplantation. Abingdon, Oxfordshire, UK: Darwin Scientific Publishing; 2000. pp 113-126.
17. Childs R, Clave E, Tisdale J, Plante M, Hensel N, Barret AJ. Succesful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral blood progenitor cell transplant: Evidence for a graft-versus-tumor effect. J Clin Oncol 1999;17:2044-2051.
18. Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int J Hematol 2002;76:376-379.
19. Georges GE, Storb R. Review of "minitransplantation": Nonmyeloablative allogeneic hematopoiteic stem cell transplantation. Int J Hematol 2003;77:3-143.
20. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Gómez-Almaguer D, López-Martínez B, Abreu-Díaz G, Bravo G, Jaime-Pérez JC. Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intesity conditioning regimens. Leukemia Lymph 2001;42:145-150.
21. Ruiz-Argüelles GJ, Gómez-Rangel JD, Ponce-de-León S, González-Déctor L, Reyes-Núñez V, Garcés-Eisele J. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. Am J Hematol 2004;75:200-204.
22. Ruiz-Argüelles GJ, López-Martínez B, Santellán-Olea MR, Abreu-Díaz G, Reyes-Núñez V, Ruiz-Argüelles A, Garcés-Eisele J. Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: A prospective study in a single instituition. Leukemia Lymph 2002;43:1509-1511.
23. Ruiz-Argüelles GJ, Gómez-Almaguer D, López- Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002;87:894-896.
24. Gómez-Almaguer D, David Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Llano O, Jaime-Pérez JC, López-Martínez B, Cantú- Rodríguez OG, Herrera-Garza JL. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biol Blood Marrow Transpl 2003;9:157-161.
25. Ruiz-Argüelles GJ, López-Martínez B, Gómez-Rangel D, Estrada E, Marín-López A, Bravo-Hernández G, Hernández JM. Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: A single institution experience. Hematology 2003;8:151-154.
26. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. BMT 2000;25:131-133.
27. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001;66:241-244.
28. Ruiz-Argüelles GJ. Outpatient programs of myeloablative chemotherapy, autologous and allogeneic bone marrow transplantation. Haematologica 2000;85:1233-1234.
29. Ruiz-Argüelles GJ, López-Martínez B, López-Ariza B. Succesful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin's disease following autologous stem cell transplantation. Arch Med Res 2003;34:242-245.
30. Ruiz-Argüelles GJ, Gómez-Rangel D, Sánchez-Anzaldo J, Ruiz-Argüelles A, Porras-Ramírez G, Luis-López A. Trasplante de células de cordón umbilical: Informe de dos casos. Medicina Univ 2002;4:233-235.
31. Ruiz-Argüelles GJ, Reyes-Núñez V, Garcés-Eisele J, Warwick RM, McKenna L, Ruiz-Reyes G, Granados J, Mercado-Díaz MA. Acquired hemoglobin S trait in an adult patient with secondary acute myelogenous leukemia allografted with matched unrelated umbilical cord blood cells using a non-ablative conditioning regimen. Haema 2005, in the press.
32. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez Rangel JD, Vela-Ojeda J, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O, Herrera-Garza JL. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients wth acute leukemia eligible for conventional allografting: A prospective study. Leukemia Lymphoma 2004;45:1191-1195.
33. Gómez-Almaguer D, Vela-Ojeda J, Jaime-Pérez JC, Guitiérrez-Aguirre CH, Cantú-Rodríguez OG, Sobrevilla-Calvo P, Rivas-Vera S, Gómez-Rangel JD, Ruiz-Argüelles GJ. Allografting in patients with severe aplastic anemia using peripheral blood stem cells and a fludarabine-based conditoning regimen: The Mexican Experience. Am J Hematol 2005, in the press.
34. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Rangel JD, Vela-Ojeda J, Karduss A, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O, Herrera-GHarza JL. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with myeloid leukemias: Results of a prospective study of the Latin American Cooperative Onco Hematology Group (LACOHG). Blood 2004;104:373b.
35. Ruiz-Argüelles GJ, López-Martínez B, Manzano C, Gómez-Rangel JD, Lobato-Mendizábal E. Significance of one human leukocyte antigen mismatch on outcome of non-myeloablative allogeneic stem cell transplantation from related donors using the Mexican schedule. BMT 2005;35:335-339.
36. Ruiz-Argüelles GJ, Gómez-Almaguer D. The Mexican approach to conduct non-ablative stem cell transplantation should not be overlooked. Int J Hematol 2003;77:526-527.
37. Vindelov L. Allogeneic bone marrow transplantation with reduced conditioning. Eur J Haematol 2001;66:73-82.
38. Ruiz-Argüelles GJ. "The Mexican approach" to conduct non-myeloablative stem cell transplantation. Eur J Haematol 2001;67:5-6.
39. Carella AM, Lerma E, Dejana A, Corsetti MT, Celesti L, Bruni R, Benvenuto F, Figari O, Parodi C, Carlier P, et al. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica 1998;83:904-909.
40. Ruiz-Arguelles GJ. Simplification, not demystification nor trivialization of stem cell transplantation. Haematologica 2001;86:E07.
41. Chandy M. Management of hematological diseases in developing countries: Socio-economic aspects. In: Schechter GP, Hoffman R, Schrier SL, editors. Hematology 1999. Washington, U.S.A: The American Society of Hematology Education Program Book; 1999. pp 73-76.
42. Gómez-Almaguer D. The simplification of the stem cell transplantation procedures in developing countries has resulted in cost-lowering and availability to more patients. Int J Hematol 2002;76(Suppl 1):380-382.
43. Barr RD. The importance of lowering costs of stem cell transplantation in devloping countries. Int J Hematol 2002; 76(Suppl 1):365-367.
44. Ruiz-Argüelles GJ, Ruiz-Reyes G. El tratamiento de las leucemias en países en desarrollo. In: Ruiz-Argüelles GJ, San-Miguel JF, editors. Actualización en Leucemias. México City, México: Editorial Médica Panamericana; 1996. pp 147-151.
45. Ruiz-Argüelles GJ. Non-myeloablative bone marrow transplantation. Arch Med Res 2003;34:554-557.
46. Ruiz-Argüelles GJ, Gómez-Almaguer D. Braking dogmata to help patients: Non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004;4:1693-1699.
47. Merton RK. The Matthew effect in science. The reward and communication systems of science are considered. Science 1968;159:56-63.
48. Gibbs WW. Lost science in the third world. Sci Am 1995;273:76-83.
49. Ruiz-Argüelles GJ, Gómez-Almaguer D. El efecto Mateo en la medicina mexicana. Bol Méd Hosp Inf Méx 2003;60:452-453.
50. Giralt S. Update of non-myeloablative stem cell transplantation for hematologic malignancies. Int J Hematol 2002;76(Suppl 1):368-375.
51. Djulbegovic B, Seidenfeld J, Bonnell A, Kumar A. Nonmyeloablative allogeneic stem cell transplantion for hematologic malignancies: A systematic review. Cancer Control 2003;10:17-41.
52. Spitzer TR. The expanding applications of non-myeloablative stem cell transplantation. Pediatr Transplant 2003;7:95-100.
53. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewsky J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Acute and chronic graft versus-host-disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transpl 2004;10:178-185.